Belgian Observational Study of 280000 Patients Links Short-Acting Bronchodilator Overuse to Higher Cardiovascular Mortality in Asthma and COPD

The study examined real-world dispensing data for more than 280000 adults with asthma or COPD, classifying exposure by annual counts of short-acting beta-agonist or muscarinic-antagonist canisters while adjusting for age, smoking, socioeconomic status, disease severity, and comorbidities. Relative mortality increases reached 12-14 percent for SABA and 36-73 percent for SAMA versus non-use; three or more canisters annually conferred additional risk compared with two or fewer.

Because the design is observational, residual confounding by unmeasured inflammation or adherence behaviors cannot be excluded, yet the dose-response pattern and consistency across two diseases strengthen the signal. Overuse here functions as a surrogate for uncontrolled airway disease rather than a direct pharmacologic cause, amplifying background cardiovascular hazard through both tachycardia and persistent systemic inflammation.

Guidelines already discourage reliever-only strategies, yet implementation gaps persist; the data suggest routine canister-count review could trigger earlier escalation of maintenance therapy or cardiology referral, particularly in primary care where most overuse originates.

Follow-up work planned by the investigators includes testing whether tighter maintenance adherence reduces canister counts and whether targeted cardiovascular risk modification alters outcomes in high-use subgroups.